Wells Fargo & Company Akero Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 20,126 shares of AKRO stock, worth $483,024. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,126
Previous 14,363
40.12%
Holding current value
$483,024
Previous $335,000
51.64%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding AKRO
# of Institutions
193Shares Held
74.2MCall Options Held
429KPut Options Held
591K-
Janus Henderson Group PLC London, X06.12MShares$147 Million0.09% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$130 Million2.2% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$126 Million3.09% of portfolio
-
Wellington Management Group LLP Boston, MA5.21MShares$125 Million0.02% of portfolio
-
Black Rock Inc. New York, NY4.89MShares$117 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.11B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...